Study to Evaluate Bi-weekly Dosing of Gemcitabine Plus Nab-Paclitaxel to Treat Metastatic Pancreatic Cancer
Status:
Terminated
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
To determine whether the occurrence of adverse events can be decreased by moving to a
bi-weekly schedule of gemcitabine plus nab-Pacitaxel for the treatment of
unresectable/metastatic pancreatic cancer.